A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.

ABSTRACT: Hepatocellular carcinoma (HCC) has a high morbidity and mortality rate worldwide, with limited treatment options. Glypican-3 (GPC3) is a glycosylphosphatidylinositol-anchored glycoprotein that is overexpressed in most HCC tissues but not in normal tissues. GPC3-targeting antibody therapy shows limited response in a clinical trial due to the lack of a tumor-specific cytotoxic T lymphocyte (CTL) response. Here, in C57/B6 mice, we demonstrated that intravenous infusion of GPC3-coupled lymphocytes (LC/GPC3⁺) elicited robust GPC3-specific antibody and CTL responses, which effectively restricted proliferation and lysed cultured-HCC cells. Treatment with LC/GPC3⁺ induced durable tumor regression in HCC-bearing C57/B6 mice. Administration of LC/GPC3⁺ induced elevat

SUBMITTER: Wu Q 

PROVIDER: S-EPMC5628867 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature